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Summary. Background: Prophylactic factor replacement,
which prevents hemarthroses and thereby reduces the
musculoskeletal disease burden in children with hemo-
philia A, requires frequent intravenous infusions (three to
four times weekly). Objective: Kids A-LONG was a
phase 3 open-label study evaluating the safety, efficacy
and pharmacokinetics of a longer-acting factor, recombi-
nant factor VIII Fc fusion protein (rFVIIIFc), in previ-
ously treated children with severe hemophilia A
(endogenous FVIII level of < 1 IU dL1 [< 1%]). Meth-
ods: The study enrolled 71 subjects. The starting
rFVIIIFc regimen was twice-weekly prophylaxis (Day 1,
25 IU kg1; Day 4, 50 IU kg1); dose (≤ 80 IU kg1)
and dosing interval (≥ 2 days) were adjusted as needed. A
subset of subjects had sequential pharmacokinetic evalua-
tions of FVIII and rFVIIIFc. The primary endpoint was
development of inhibitors (neutralizing antibodies). Sec-
ondary endpoints included pharmacokinetics, annualized
bleeding rate (ABR), and number of infusions required to
control a bleed. Results: No subject developed an inhibi-
tor to rFVIIIFc. Adverse events were typical of a pediat-
ric hemophilic population. The rFVIIIFc half-life was
prolonged relative to that of FVIII, consistent with obser-
vations in adults and adolescents. The median ABR was
1.96 overall, and 0.00 for spontaneous bleeds; 46.4% of
subjects reported no bleeding episodes on study. Ninety-
three per cent of bleeding episodes were controlled with
one to two infusions. The median average weekly
rFVIIIFc prophylactic dose was 88.11 IU kg1. At study
end, 62 of 69 subjects (90%) were infusing twice weekly.
Among subjects who had been previously receiving FVIII
prophylaxis, 74% reduced their dosing frequency with
rFVIIIFc. Conclusion: Twice-weekly infusions with
rFVIIIFc were well tolerated and yielded low bleeding
rates in children with severe hemophilia A.
Keywords: children; coagulation factor VIII; hemophilia A;
prophylaxis; recombinant fusion proteins.
Introduction
In patients with severe hemophilia A, recurrent spontane-
ous bleeding into joints and muscles is common, and results
in chronic pain and impaired joint function [1,2]. Early pro-
phylactic replacement of coagulation factor VIII (FVIII)
has been shown to improve long-term clinical outcomes
[1,3,4]. However, the frequent intravenous infusions (three
to four times weekly) required to maintain protective FVIII
levels above 1 IU dL1 (1%) [3,5] can constitute a barrier
to the adoption of prophylaxis [6–8], particularly for chil-
dren with challenging venous access and in whom more fre-
quent infusions may be required, owing to a shorter FVIII
half-life than that in adults [9]. A FVIII molecule with a
prolonged circulation time has the potential to improve the
adoption of and adherence to prophylaxis, and may posi-
tively impact therapeutic outcomes [8].
Recombinant FVIII Fc fusion protein (rFVIIIFc) is
composed of a single molecule of recombinant FVIII
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(rFVIII) covalently fused to the dimeric Fc domain of
IgG1 [10]; the protein binds the neonatal Fc receptor, and
utilizes the IgG recycling pathway to extend plasma half-
life [11]. In the phase 3 A-LONG study [12] of previously
treated adults and adolescents with hemophilia A,
rFVIIIFc had an approximately 1.5-fold longer half-life
than rFVIII, and was shown to be safe and efficacious
for prophylaxis. Here, we report the results of a multicen-
ter, open-label phase 3 study evaluating the safety,
efficacy and pharmacokinetics (PK) of rFVIIIFc in previ-
ously treated children aged < 12 years with severe hemo-
philia A.
Materials and methods
Study population
This was a phase 3 open-label multicenter study of
rFVIIIFc in pediatric patients with severe hemophilia A.
The protocol was approved by individual institutional
review boards; the study was conducted in accordance
with the International Conference on Harmonization
guidelines for Good Clinical Practice, and registered with
ClinicalTrials.gov (NCT01458106). All subjects’ guardians
provided written informed consent; if appropriate, sub-
jects also provided assent.
Children aged < 12 years with severe hemophilia A
(endogenous FVIII activity of < 1 IU dL1 [< 1%]) or a
documented genotype known to produce severe hemo-
philia A [13,14] were eligible for inclusion in the study.
In accordance with regulatory guidance [15], and to
allow for evaluation of the antigenicity of rFVIIIFc, the
study was limited to previously treated patients. Patients
were considered to have been previously treated if they
had received treatment with any recombinant or plasma-
derived FVIII product for at least 50 exposure days
(EDs; defined as a 24-h period during which replacement
factor was administered one or more times). Patients
with a history of or currently detectable inhibitor (i.e.
neutralizing antibody activity at screening of
≥ 0.6 BU mL1 determined with the Nijmegen-modified
Bethesda assay), history of anaphylaxis associated with
any FVIII or intravenous immunoglobulin administra-
tion, or other coagulation disorders in addition to hemo-
philia A, were excluded. Additional criteria are specified
in Table S1.
Study design
The study had a single prophylactic treatment arm with
twice-weekly intravenous infusions of rFVIIIFc
(25 IU kg1 on Day 1 and 50 IU kg1 on Day 4)
(Fig. 1). Adjustments in dose (to a maximum of
80 IU kg1) and interval (to a minimum of every 2 days)
were allowed, based on a subject’s available PK data and
observed bleeding patterns (Fig. S1).
As per regulatory guidance [15], a subset of subjects
(a minimum of 12 in each cohort) had comparative PK
assessments with their prestudy FVIII product and
rFVIIIFc prior to initiation of rFVIIIFc prophylaxis.
For PK assessments, a washout period of at least 72 h
with no FVIII treatment was required prior to adminis-
tration of either prestudy FVIII (50 IU kg1, rounded
up to the nearest 250-IU increment, with sampling up to
48 h) or administration of rFVIIIFc (50 IU kg1, with
sampling up to 72 h); all samples collected were
analyzed for FVIII activity in plasma at a central
laboratory.
The study sample size was based on clinical consider-
ations and regulatory requirements [15], with a target
enrollment of ~ 68 subjects (~ 34 aged < 6 years, and
~ 34 aged 6 years to < 12 years); taking into account a
25% drop-out rate, this would ensure that at least 25 sub-
jects per age cohort had valid inhibitor test results follow-
ing at least 50 rFVIIIFc EDs. The study was terminated
when at least 12 subjects in each age group had adequate
PK data, and ≥ 50 subjects had valid inhibitor test results
from testing at 50 EDs or more.
The dose and dosing interval compliance rate of each
subject with the prescribed prophylactic dosing regimen
was calculated on both a per-injection basis and a per-
subject basis. Compliance evaluations considered the
nominal dose taken per infusion as compared with the
nominal dose prescribed, and the actual day of treatment
as compared with the prescribed day of treatment. A sub-
ject with ≥ 80% of doses taken within 80–125% of the
prescribed dose and ≥ 80% of doses taken within  24 h
of the prescribed day was considered to be ‘dose compli-
ant’ and ‘dosing interval compliant’, respectively.
Outcome measures
The primary endpoint was the development of inhibitors
(identified by a Nijmegen-modified Bethesda assay titer of
≥ 0.6 BU mL1, and confirmed in two separate samples
drawn approximately 2–4 weeks apart), with testing being
conducted at each clinic visit prior to dosing; all samples
were analyzed at a central laboratory. A washout period
of at least 48 h was required prior to inhibitor testing
(washout was confirmed from a trough sample at base-
line); samples were heat-inactivated prior to inhibitor test-
ing to inactivate any residual rFVIIIFc that may have
been present. Testing for inhibitors was conducted within
the first 10–15 EDs to rFVIIIFc and at all scheduled vis-
its. If the 10–15 ED testing did not occur at a scheduled
study visit, an additional visit was scheduled to complete
the testing. If inhibitor development was suspected at any
time during the study (for example, if the expected
plasma FVIII activity levels were not attained or if the
bleeding episode was not controlled with an expected
dose), the subject was tested for inhibitors by a central
laboratory.
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Secondary endpoints included FVIII activity (PK)
measurements, annualized bleeding rate (ABR) by type
(spontaneous or traumatic) and location of bleeding,
rFVIIIFc dose administered for treatment of a bleeding
episode, and subject’s rating of the response to rFVIIIFc
for the treatment of bleeding. The protocol for the treat-
ment of a bleeding episode is detailed in Fig. S2. Clinical
and laboratory safety assessments were also performed,
and the development of anti-rFVIIIFc binding antibodies
was assessed at baseline and at each clinic visit by means
of an electrochemiluminescence assay [16] for rFVIIIFc-
binding antibodies.
Analytical methods
Statistical analyses were primarily descriptive in nature,
with data being summarized overall and by age cohort.
Safety analyses were performed with data from all subjects
(i.e. those who received at least one dose of a prestudy
FVIII treatment for the purpose of evaluating PK, or at
least one dose of rFVIIIFc); efficacy analyses included data
only from subjects who received at least one dose of
rFVIIIFc. Efficacy data from the last 3 months on study
were analyzed to account for dosage adjustments that may
have occurred early in the study, as well as any underlying
physiologic changes related to the adjustment to a new
treatment regimen (e.g. changing from episodic to prophy-
lactic treatment) that may have contributed to a higher
initial rate of bleeding.
Efficacy outcomes were evaluated by the use of descrip-
tive statistics (median and interquartile range [IQR]). For
prestudy versus on-study dosing analyses, the prestudy
regimen evaluated was the most recent regimen that the
subject had received prior to the study. Actual sampling
times, actual doses of rFVIIIFc, nominal doses of pre-
study FVIII and actual injection durations were used for
PK analyses. The use of nominal doses in analyses of pre-
study FVIII was necessary because of geographic differ-
ences in the availability of prestudy product information
(for example, in the USA, actual vial strength informa-
tion for commercial FVIII products was available,
whereas only nominal vial strength information was avail-
able outside the USA).
PK parameters based on FVIII activity as measured
with the one-stage clotting assay are presented as arithme-
tic means and 95% confidence intervals (CIs); compara-
tive intrasubject ratios (rFVIIIFc/prestudy FVIII) of the
PK parameters are expressed as medians and IQRs.
Results
Study population
A total of 71 male subjects (< 6 years of age, n = 36;
6 years to < 12 years of age, n = 35) were enrolled at 23
investigational sites in eight countries between 9 October
2012 and 5 December 2013; 67 subjects (94.4%) com-
pleted the study (Fig. 2). Subjects’ demographics and
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Fig. 1. Study design. Kids A-LONG was an open-label, multicenter evaluation of recombinant FVIII Fc fusion protein (rFVIIIFc) in pediatric
previously treated patients with severe hemophilia A. The study enrolled 71 subjects into two age cohorts (< 6 years of age; 6 years to
< 12 years of age). A sufficient number of subjects (at least 12 from each age cohort) were to be enrolled into a comparative pharmacokinetic
(PK) subgroup for the sequential evaluation of PK profiles for prestudy FVIII and rFVIIIFc (FVIII evaluation was to occur at least 28 days
prior to the first rFVIIIFc dose). The time required for screening and PK assessments was approximately 8–12 weeks. All subjects began twice-
weekly prophylactic treatment with rFVIIIFc, with a starting regimen of 25 IU kg1 on Day 1 and 50 IU kg1 on Day 4. If a subject had at
least five exposure days (EDs) of rFVIIIFc without safety concerns, surgery was allowed. The duration of study participation per subject was
~ 28 weeks for the treatment and follow-up periods, after which subjects had the option to enter into an extension study. *A washout period
of at least 72 h with no FVIII treatment was required prior to administration of prestudy FVIII and prior to rFVIIIFc for PK assessments.
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baseline characteristics were representative of the global
pediatric hemophilia A population (Table 1). As expected
for a pediatric population, no enrolled subjects were posi-
tive for human immunodeficiency virus or hepatitis C
virus infection. A family history of inhibitors, which was
not prohibited per protocol, was reported in six study
subjects (8.5%), and a large proportion of subjects had
genotypes known to be associated with inhibitor develop-
ment [13,14] (e.g. intron 22 inversions in 26 subjects
[36.6%] and nonsense mutations in nine subjects
[12.7%]). The majority of subjects (88.7%) were receiving
FVIII prophylaxis at study entry, and ~ 75% of these
subjects were infusing three or more times per week.
Of the 71 enrolled subjects, 69 were exposed to
rFVIIIFc during the study. The median time on study
was 26.3 weeks, and a total of 61 subjects (88.4%) had
≥ 50 rFVIIIFc EDs on study. The majority (69.6%) of
subjects were adherent to their prescribed dose and inter-
val, although the dose-and-interval compliance rate was
lower in the younger cohort (51.4%) than in the older
cohort (88.2%). This was likely attributable to the proto-
col requirement of ‘rounding up’ to the nearest dose
increment in younger subjects with low body weights, as
shown by the fact that, whereas dosing interval compli-
ance was similar in the younger and older cohorts (88.6%
and 97.1%, respectively), compliance with the prescribed
dose was not (60.0% and 91.2%, respectively).
Safety
No subjects developed an inhibitor to rFVIIIFc. The
estimated inhibitor incidence rate was 0.00% (95% CI
0.00–5.06%) overall, and 0.00% (95% CI 0.00–5.87%)
among 61 subjects with at least 50 rFVIIIFc EDs. No
subject had a positive test result for anti-rFVIIIFc bind-
ing antibodies that emerged with rFVIIIFc treatment.
Anti-rFVIIIFc binding antibodies (i.e. anti-drug antibod-
ies) were detected at baseline in seven subjects (< 6 years
of age, n = 4; 6 years to < 12 years of age, n = 3); in all
cases, the positive anti-rFVIIIFc binding antibody results
were obtained prior to the first dose of rFVIIIFc. In
these seven subjects, the positive anti-rFVIIIFc binding
antibody result was followed by a negative result during
the course of the study (four subjects), or fluctuated but
remained positive through all study visits (three sub-
jects). Importantly, none of the anti-rFVIIIFc binding
antibodies detected was directed against the Fc portion
of rFVIIIFc. These anti-rFVIIIFc binding antibodies
had no discernable impact on PK assessments, adverse
events (AEs), or bleeding rates. Further evaluation of
the potential impact of anti-rFVIIIFc binding antibodies
on PK and FVIII activity was not feasible, owing to the
small number subjects with positive test results.
rFVIIIFc was generally well tolerated, with a pattern
of AEs typical of the pediatric population studied. Of the
69 subjects treated with rFVIIIFc, 59 (85.5%) reported at
least one AE on study, giving a total of 213 AEs
(Table 2). The majority of the AEs were judged by the
investigator to be unrelated to rFVIIIFc treatment. Two
non-serious AEs (myalgia and erythematous rash) were
judged by investigators to be related to rFVIIIFc
(Table S3). No subjects discontinued rFVIIIFc because of
an AE; one subject withdrew prior to treatment with
rFVIIIFc, owing to an event of Klebsiella sepsis in the
71 Patients enrolled
(all included in safety analysis)
36 Enrolled in < 6-year old cohort 35 Enrolled in 6-year-old to < 12-year-old cohort
25 Enrolled in PK subgroup* 35 Enrolled in PK subgroup*
34 Completed the study
34 Received at least one
dose of rFVIIIFc and were
included in efficacy analysis
33 Completed the study
1 Discontinued prematurely3 Discontinued prematurely
1 Withdrawn per protocol2 Withdrew consent1 Had adverse event
11 Enrolled in non-PK subgroup 0 Enrolled in non-PK subgroup
35 Received at least one
dose of rFVIIIFc and were
included in efficacy analysis
Fig. 2. Subject disposition. Patients were assigned to the appropriate age cohort (< 6 years of age or 6 years to < 12 years of age) at the time
of screening; the assigned cohort was used in all analyses unless otherwise stated. All enrolled patients were included in the safety analysis; two
subjects received prestudy FVIII for the purpose of evaluating pharmacokinetics (PK), but were not treated with recombinant FVIII Fc fusion
protein (rFVIIIFc), and were therefore not included in the efficacy analysis. Sixty patients were enrolled in the PK subgroup and underwent
PK assessments with both prestudy FVIII and rFVIIIFc prior to the initiation of an rFVIIIFc prophylaxis regimen. Of these, 51 subjects
(< 6 years of age, n = 23; 6 years to < 12 years of age, n = 28) had complete evaluable PK profiles for both prestudy FVIII and rFVIIIFc.
Four subjects did not complete the study: two withdrew consent, one was withdrawn per protocol (washout attempts prior to rFVIIIFc PK
assessment were unsuccessful), and one had an adverse event (infection of a central venous catheter) that led to study discontinuation prior to
receipt of treatment with rFVIIIFc. *Of the 60 subjects in the PK subgroup, five were exempted from PK assessment with prestudy FVIII at
screening because they had historical data (i.e. within 14 months of screening) from a prior PK assessment with FVIII.
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setting of a central venous catheter infection. Five
subjects (7.2%) experienced a total of seven serious AEs
on study (two subjects experienced two events each); none
was judged by investigators to be related to rFVIIIFc
(Table 2). There were no reports of anaphylaxis or vascu-
lar thrombotic events with rFVIIIFc, and no deaths.
PK analyses
Of the 60 subjects dosed with rFVIIIFc in the PK subgroup,
54 (< 6 years of age, n = 23; 6 years to < 12 years of age,
n = 31) had evaluable PK data from the one-stage clotting
assay. The activity–time profiles in both age cohorts,
adjusted for baseline and residual prestudy FVIII activity,
were adequately characterized by non-compartmental
analysis, with moderate intersubject variability (Fig. S3).
The mean terminal half-lives of rFVIIIFc in subjects
< 6 years of age and 6 years to < 12 years of age were
12.67 h (95% CI 11.23–14.11) and 14.88 h (95% CI 11.98–
17.77), respectively (Table 3). An age-dependent effect on
clearance was observed, with mean clearance being higher
in the younger cohort (3.60 mL h1 kg1 [95% CI 3.13–
4.07]) than in the older cohort (2.78 mL h1 kg1
[95% CI 2.44–3.13]). Incremental recovery of rFVIIIFc
was consistent between the age cohorts (mean of approxi-
mately 2 IU dL1 per IU kg1) (Table 3), which is similar
to what has been observed previously with FVIII products
[17,18].
A comparison of FVIII and rFVIIIFc PK was per-
formed for 46 subjects (< 6 years of age, n = 19; 6 years
to < 12 years of age, n = 27) for whom data for both
products were available. As subjects used various FVIII
products for the prestudy PK assessment, a formal sum-
mary comparing rFVIIIFc with prestudy FVIII PK was
not planned. However, post hoc summaries were prepared
for two of the most common prestudy treatments, i.e. Ad-
vate and Helixate/Kogenate (Fig. 3A,B). Across all pre-
study products, an intrasubject comparison of rFVIIIFc
and FVIII half-lives yielded ratios ranging from 0.79 to
2.98 (Fig. 3C,D).
Efficacy
Overall, 46.4% of subjects reported no bleeding events
on study. The median ABRs were 1.96 (IQR 0.00–3.96)
overall, and 0.00 (IQR 0.00–4.01) over the last 3 months
of the study (among subjects with ≥ 24 weeks on study)
(Table 4). Subjects who had previously been receiving
Table 1 Baseline characteristics of study subjects
Age cohort < 6 years of age (N = 36)
6 years to < 12 years of
age (N = 35) Total (N = 71*)
Age (years), median (minimum, maximum) 4.0 (1, 5) 8.0 (6, 11) 5.0 (1, 11)
Weight (kg), median (minimum, maximum) 17.25 (13.0, 23.8) 31.35 (19.1, 59.6) 21.30 (13.0, 59.6)
Race, n (%)
White 24 (66.7) 24 (68.6) 48 (67.6)
Black 4 (11.1) 5 (14.3) 9 (12.7)
Asian 4 (11.1) 1 (2.9) 5 (7.0)
Other 4 (11.1) 5 (14.3) 9 (12.7)
Geographic region, n (%)
Europe 17 (47.2) 15 (42.9) 32 (45.1)
North America 9 (25.0) 11 (31.4) 20 (28.2)
Other 10 (27.8) 9 (25.7) 19 (26.8)
F8 genotype, n (%)
Intron 22 inversion 17 (47.2) 9 (25.7) 26 (36.6)
Frameshift 9 (25.0) 7 (20.0) 16 (22.5)
Missense 5 (13.9) 7 (20.0) 12 (16.9)
Nonsense 2 (5.6) 7 (20.0) 9 (12.7)
Intron 1 inversion 1 (2.8) 2 (5.7) 3 (4.2)
Unknown 1 (2.8) 2 (5.7) 3 (4.2)
Not found 1 (2.8) 1 (2.9) 2 (2.8)
Prestudy FVIII regimen, n (%)
Episodic 3 (8.3) 5 (14.3) 8 (11.3)
Prophylaxis 33 (91.7) 30 (85.7) 63 (88.7)
Once weekly 3 (9.1) 0 (0.0) 3 (4.8)
Twice weekly 7 (21.2) 6 (20.0) 13 (20.6)
Three times weekly 15 (45.5) 16 (53.3) 31 (49.2)
Every other day 8 (24.2) 8 (26.7) 16 (25.4)
Estimated total number of bleeds in the
prior 12 months, median (minimum maximum)
2 (0, 16) 4 (0, 36) 2 (0, 36)
One or more target joints, n (%) 6 (16.7) 7 (20.0) 13 (18.3)
Family history of inhibitors, n (%) 3 (8.3) 3 (8.6) 6 (8.5)
*Sixty-nine of 71 subjects were exposed to recombinant factor VIII Fc fusion protein (rFVIIIFc) during the study; two subjects received a dose
of prestudy factor VIII (FVIII) for pharmacokinetic evaluation, but withdrew prior to receiving rFVIIIFc.
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FVIII prophylaxis showed a lowering of their median
ABR with rFVIIIFc (< 6 years of age, n = 32, prestudy,
1.50, on study, 0.00; 6 years to < 12 years of age, n = 30,
prestudy, 2.50, on study, 2.01). Across both age cohorts,
the median ABR was zero for spontaneous and traumatic
bleeding episodes, and for spontaneous joint bleeding epi-
sodes (Table 4). In subjects with one or more target joints
at baseline, the median ABR for the 12 months prior to
the study was 8.0 (IQR 4.0–11.0), as compared with 0.0
(IQR 0.0–5.8) on study (Table 4).
The median average dosing interval for rFVIIIFc
prophylaxis was 3.5 days (Table 5). The majority (89.9%)
of subjects made no changes to their dosing interval over
the course of the study, indicating that the dosing regi-
mens selected for study were appropriate for a pediatric
population. As compared with their previous FVIII pro-
phylactic regimen, 46 of 62 subjects (74.2%) reduced their
dosing frequency with rFVIIIFc (Table S2). The median
average weekly rFVIIIFc dose over the course of the
study was 88.11 IU kg1 weekly (IQR 80.29–103.08).
Among subjects previously receiving FVIII prophylaxis,
there was a trend towards a lower median average weekly
dose with rFVIIIFc than with FVIII (< 6 years of age,
from 97.75 IU kg1 weekly [IQR 76.50–119.00] prestudy,
to 90.55 IU kg1 weekly [IQR 83.19–104.59] on study;
6 years to < 12 years of age, from 102.50 IU kg1 weekly
[IQR 78.00–129.00] prestudy, to 87.66 IU kg1 weekly
[IQR 79.71–104.05] on study), whereas bleeding rates
remained similar to, or lower than, those observed with
the prior FVIII regimen.
A total of 86 bleeding episodes occurred in 37 subjects
on study. A single infusion was sufficient to resolve the
majority (81.4%) of bleeding episodes; 93.0% were
resolved with one or two infusions. Among the infusions
evaluated by subjects for response, 89.4% were rated as
producing an excellent or good response. Overall, the
median dose per infusion for resolution of a bleed was
49.7 IU kg1 per bleeding episode (Table 5). There were
no major surgical procedures performed with rFVIIIFc
on study. In seven minor surgical procedures in seven
subjects (three subcutaneous intravenous access device
placement procedures, three dental extractions, and one
colonoscopy/endoscopy), the hemostatic response with
rFVIIIFc was evaluated by the investigator as excellent
(n = 5) or good (n = 2).
Discussion
The results of this phase 3 pediatric rFVIIIFc study
confirm the findings of a similar study in adults and
Table 2 Summary of adverse events (AEs) (≥ 3% in the total popu-
lation)
Preferred term
< 6 years
N = 35*
6 years to
< 12 years
N = 34*
Total
N = 69*
Subjects with at least
one AE, n (%)
31 (88.6) 28 (82.4) 59 (85.5)
Cough 7 (20.0) 6 (17.6) 13 (18.8)
Upper respiratory
tract infection
7 (20.0) 2 (5.9) 9 (13.0)
Fall 4 (11.4) 2 (5.9) 6 (8.7)
Nasopharyngitis 2 (5.7) 4 (11.8) 6 (8.7)
Upper abdominal pain 1 (2.9) 4 (11.8) 5 (7.2)
Head injury 3 (8.6) 2 (5.9) 5 (7.2)
Headache 1 (2.9) 4 (11.8) 5 (7.2)
Vomiting 3 (8.6) 2 (5.9) 5 (7.2)
Diarrhea 3 (8.6) 1 (2.9) 4 (5.8)
Ear infection 2 (5.7) 2 (5.9) 4 (5.8)
Fatigue 1 (2.9) 3 (8.8) 4 (5.8)
Pain in extremity 2 (5.7) 2 (5.9) 4 (5.8)
Pharyngitis 2 (5.7) 2 (5.9) 4 (5.8)
Seasonal allergy 2 (5.7) 2 (5.9) 4 (5.8)
Tonsillitis 2 (5.7) 2 (5.9) 4 (5.8)
Arthralgia 2 (5.7) 1 (2.9) 3 (4.3)
Joint swelling 2 (5.7) 1 (2.9) 3 (4.3)
Pyrexia 1 (2.9) 2 (5.9) 3 (4.3)
Rhinorrhea 2 (5.7) 1 (2.9) 3 (4.3)
Viral upper respiratory
tract infection
3 (8.6) 0 3 (4.3)
Subjects with at least one
SAE, n (%)†
4 (11.4) 1 (2.9) 5 (7.2)
SAE, serious adverse event. *Based on number of subjects receiving
at least one dose of recombinant factor VIII Fc fusion protein
(rFVIIIFc). †Five of 69 subjects treated with rFVIIIFc (7.2%) expe-
rienced a total of seven SAEs after at least one dose of rFVIIIFc
(two subjects experienced two events each): head injury in two sub-
jects, and the remaining SAEs (fall, Bacillus infection, Escherichia
infection, croup infectious, and metapneumovirus infection) in one
subject each.
Table 3 Recombinant factor VIII Fc fusion protein (rFVIIIFc) pharmacokinetics
Pharmacokinetic parameter, mean (95% CI): < 6 years (N = 23) 6 years to < 12 years (N = 31)
IR (IU dL1 per IU kg1) 1.92 (1.80–2.04) 2.44 (2.07–2.80)
t1/2 (h) 12.67 (11.23–14.11) 14.88 (11.98–17.77)
CL (mL h1 kg1) 3.60 (3.13–4.07) 2.78 (2.44–3.13)
DNAUC (IU 9 h dL1 per IU kg1) 30.04 (26.45–33.63) 41.87 (34.00–49.75)
MRT (h) 17.24 (15.40–19.07) 20.90 (17.06–24.74)
Vss (mL kg
1) 58.58 (54.90–62.27) 52.13 (45.25–59.01)
CI, confidence interval; CL, clearance; DNAUC, dose normalized area under the concentration–time curve; IR, incremental recovery;
MRT, mean residence time; t1/2, half-life; Vss, volume of distribution at steady state. The pharmacokinetic data reported are arithmetic mean
(95% CI), derived from non-compartmental analysis of the one-stage clotting assay data; the pharmacokinetic parameters obtained from the
one-stage assay were consistent with results from the two-stage chromogenic assay (data not shown).
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adolescents with severe hemophilia A, in which rFVIIIFc
had a prolonged half-life relative to rFVIII [12,19]. Fur-
thermore, rFVIIIFc was well tolerated and efficacious for
the prophylaxis and treatment of bleeding in children
< 12 years of age.
This is the first report of a pediatric study utilizing a
long-acting factor therapy for routine prophylaxis. The
benefits of early initiation of prophylaxis in children with
hemophilia A include reduced bleeding, improved radio-
logic joint scores [3,4,20], an increased capacity for physi-
cal activity, and maintenance of bone health [21,22]. In
this study, twice-weekly rFVIIIFc prophylaxis resulted in
low ABRs for spontaneous bleeding episodes, including
joint bleeding episodes, and 46.4% of study subjects
reported no bleeding events on study. Subjects receiving a
prestudy FVIII regimen of three intravenous infusions
per week experienced an approximately 33% reduction in
annual infusions with twice-weekly rFVIIIFc prophylaxis.
Additionally, rFVIIIFc was highly efficacious for the
treatment of bleeding events, with 93.0% of subjects
requiring only one to two rFVIIIFc infusions to manage
a bleeding episode. These data are consistent with those
expected for an efficacious FVIII therapy, and are in the
range reported in prior rFVIII trials in pediatric popula-
tions [17,18].
Inhibitors develop in up to 30% of previously
untreated patients with hemophilia A [23], and have also
been reported in previously treated patients, although
rarely [24,25]. No inhibitors developed with rFVIIIFc
treatment, even among subjects with a genotype typically
associated with inhibitor development. These results are
similar to those reported in pediatric trials of previously
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Fig. 3. Comparison of recombinant FVIII Fc fusion protein (rFVIIIFc) and prestudy recombinant FVIII pharmacokinetic (PK) parameters. A
comparison of the FVIII PK parameters for rFVIIIFc versus prestudy FVIII was performed for 46 subjects (< 6 years of age, n = 19; 6 years
to < 12 years of age, n = 27) with the one-stage clotting assay, and the ratio of rFVIIIFc PK to the PK of the prior FVIII for each subject
was calculated. Representative summaries from subjects who received prestudy therapy with the most common prestudy treatments, Advate
(A) or Helixate/Kogenate (B), are shown. The box represents the median and interquartile range, the ‘whiskers’ represent the minimum and
maximum, and the reference unity line marks the point at which PK parameters for rFVIIIFc and prestudy FVIII are the same. For all sub-
jects in the PK subgroup, an intrasubject comparison of FVIIIFc and prestudy FVIII PK was performed; data for the half-life comparison are
shown by age cohort and prestudy FVIII product (C, D). CL, clearance; IR, incremental recovery; t1/2, half-life; pdFVIII, plasma-derived
FVIII; Vss, volume of distribution at steady state. Data not shown for subjects for whom only historical FVIII PK data were available; these
included one subject in the < 6-year cohort who used Advate prestudy, and two subjects in the 6-year to < 12-year cohort who used Refacto
AF/Xyntha prestudy.
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treated patients with other conventional or modified
FVIII therapies [17,18,26]. Coupled with the lack of
inhibitors observed in the A-LONG study (which
included 110 subjects with ≥ 50 EDs)[12], these data sug-
gest rFVIIIFc may be no more immunogenic than native
FVIII molecules, with a low risk of inhibitor development
in the previously treated patient population. Anti-
rFVIIIFc binding antibodies were detected at baseline in
some subjects in this study; however, these antibodies
were not directed against the Fc portion of rFVIIIFc,
and had no apparent clinical impact. These ‘non-inhibi-
tory’ or ‘non-neutralizing’ anti-rFVIII antibodies have
been previously reported in people with and without
hemophilia [27–29], and their clinical significance remains
unclear [30,31]. Further investigation is needed to fully
understand the immunologic profile of rFVIIIFc, includ-
ing the potential for inhibitor development with long-term
treatment or in previously untreated patients, and
whether rFVIIIFc has any immunologic advantages as
compared with conventional therapies. The long-term
safety and efficacy of rFVIIIFc are being studied in the
ASPIRE extension study (ClinicalTrials.gov Identifier
NCT01454739), and a study evaluating the safety and
efficacy of rFVIIIFc in previously untreated patients is
currently enrolling (ClinicalTrials.gov Identifier
NCT02234323).
An age-dependent effect on rFVIIIFc PK was
observed, as has been reported for rFVIII [9,32,33].
Despite the age-related increase in clearance, the half-life
prolongation as compared with prestudy FVIII was
consistent across age groups, and was consistent with the
half-life extension previously reported in adults and
adolescents [12,19]. There was greater variability in the
prestudy/on-study half-life ratios in children than in
adults, with some subjects showing a nearly three-fold
prolongation of half-life, and others failing to show a
beneficial effect (Fig. 3). Some of the observed variability
can be explained by inherent physiologic differences in
PK in pediatric patients [9,32]. Individual variability in
the Fc-mediated recycling mechanism for rFVIIIFc is
also possible, although this has not been investigated or
reported for other Fc fusion proteins. Certain elements
of the study design may also have contributed to the var-
iability in prestudy/on-study half-life ratios, including the
Table 4 Summary of annualized bleeding rate (ABR) by subgroup
ABR Median IQR Range
Per subject, overall
All subjects (n = 69) 1.96 0.00–3.96 0.0–27.2
< 6-year cohort (n = 35) 0.00 0.00–3.96 0.0–10.5
6-year to < 12-year cohort
(n = 34)
2.01 0.00–4.04 0.0–27.2
Per subject, last 3 months on study*
All subjects (n = 59) 0.00 0.00–4.01 0.0–12.0
< 6-year cohort (n = 26) 0.00 0.00–4.01 0.0–12.0
6-year to < 12-year cohort
(n = 33)
0.00 0.00–4.01 0.0–8.0
By bleeding episode type and location
Spontaneous
All subjects (n = 69) 0.00 0.00–0.00 0.0–19.8
< 6-year cohort (n = 35) 0.00 0.00–0.00 0.0–7.9
6-year to < 12-year cohort
(n = 34)
0.00 0.00–0.00 0.0–19.8
Spontaneous joint
All subjects (n = 69) 0.00 0.00–0.00 0.0–14.8
< 6-year cohort (n = 35) 0.00 0.00–0.00 0.0–6.0
6-year to < 12-year cohort
(n = 34)
0.00 0.00–0.00 0.0–14.8
Traumatic
All subjects (n = 69) 0.00 0.00–2.04 0.0–7.9
< 6-year cohort (n = 35) 0.00 0.00–2.01 0.0–6.5
6-year to < 12-year cohort
(n = 34)
0.00 0.00–2.12 0.0–7.9
By presence of target joints at baseline
Subjects with ≥ 1 target joint (n = 13)
Prestudy (12 months prior) 8.00 4.00–11.00 1.0–28.0
On study 0.00 0.00–5.83 0.0–27.2
Subjects with no target joints (n = 56)
Prestudy (12 months prior) 2.00 1.00–4.00 0.0–36.0
On study 1.97 0.00–3.87 0.0–10.5
IQR, interquartile range. *Among 59 subjects (< 6-year cohort, n = 26;
6-year to < 12-year cohort, n = 33) with at least 24 weeks on study.
Table 5 Recombinant factor VIII Fc fusion protein (rFVIIIFc) dosing summary
Age cohort < 6 years (N = 35)
6 years to < 12 years
(N = 34) Total (N = 69)
rFVIIIFc prophylaxis
Average weekly dose (IU kg1), median (IQR)
Overall 91.63 (84.72–104.56) 86.88 (79.12–103.08) 88.11 (80.29–103.1)
Last 3 months* 101.86 (80.50–117.50) 88.97 (79.79–105.11) 92.51 (79.79–109.00)
Average dosing interval (days), median (IQR)
Overall 3.50 (3.47–3.51) 3.49 (3.46–3.51) 3.49 (3.46–3.51)
Last 3 months* 3.49 (3.45–3.52) 3.49 (3.46–3.52) 3.49 (3.45–3.52)
Treatment of bleeding
Dose per bleeding episode
Bleeding episodes, n 38 48 86
Average dose per infusion( IU kg1), median (minimum, maximum) 51.35 (13.9, 91.3) 48.15 (14.0, 77.0) 49.69 (13.9, 91.3)
Total dose (IU kg1), median (minimum, maximum) 56.40 (13.9, 200.0) 53.49 (14.0, 196.6) 54.90 (13.9, 200.0)
IQR, interquartile range. *Among 59 subjects (<6 years cohort, n = 26; 6 to <12 years cohort, n = 33) with at least 24 weeks on study.
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variety of FVIII products used for comparison, and vari-
ations in the availability of prestudy product information
in certain geographic locations. Additionally, the study
was designed to minimize blood draw volume in children,
so a relatively sparse sampling schedule was used as com-
pared with the adult study, which limited the information
available for PK assessments [34]. It is known that von
Willebrand factor (VWF) interacts with FVIII in the cir-
culation, protecting it from proteolytic degradation and
possibly providing structural stability to the protein [35].
However, this interaction also limits the ability to extend
FVIII half-life beyond that of VWF (~ 10–25 h [36])
[19,37–39]. Whereas VWF levels have been shown to be
correlated with rFVIIIFc half-life and extended dosing
intervals for rFVIIIFc in adults [12,19,40], VWF levels
were not measured in this study, in part because of the
desire to limit blood sampling in pediatric subjects.
In addition to study design elements that may have
contributed to variability in the PK data, this study had a
few other limitations that are typical for pediatric hemo-
philia trials. The challenges of clinical trial design related
to the recruitment of patients affected by hemophilia A
[41] are magnified in a pediatric study. By design and as
requested by regulatory agencies [15], the study popula-
tion was limited to previously treated patients, and
excluded subjects with a history of inhibitors, which fur-
ther reduced the pool of subjects and yielded a popula-
tion at lower risk for the development of inhibitors.
Additionally, the study had a single arm, and thus did
not concurrently compare rFVIIIFc with other FVIII
products, and nor was it designed to maximize dosing
intervals with rFVIIIFc. However, this trial enrolled a rel-
atively large number of subjects representative of the glo-
bal pediatric hemophilia A population, and, as the
protocol allowed for dosing flexibility to represent a range
of dosing regimens, the study was reflective of the real-
world setting.
In conclusion, rFVIIIFc was well tolerated and effica-
cious in the prevention and treatment of bleeding events
in children with severe hemophilia A, with no evidence of
increased immunogenicity. The PK and efficacy results
support the potential for extended-interval dosing and a
reduced infusion frequency with rFVIIIFc as compared
with conventional FVIII products, with excellent control
of bleeding. The technological advance represented by Fc
fusion may also have broader implications in other
chronic diseases affecting pediatric populations where a
reduction in injection frequency would be advantageous,
and narrows the gap between current hemophilia thera-
pies and new research focused on curative technologies
that can lessen or eliminate the need for prophylaxis
[42,43]. By mitigating the barriers presented by frequent
infusions, rFVIIIFc may facilitate the more widespread
adoption of early initiation of prophylaxis in younger
subjects, which has the potential to positively impact on
long-term outcomes.
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